Who makes Moxonidine 0.2 MG?

Moxonidine 0.2 MG is developed by Italo Biaggioni.

What development phase is Moxonidine 0.2 MG in?

Moxonidine 0.2 MG is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Moxonidine 0.2 MG

Italo Biaggioni · FDA-approved active Small molecule Quality 5/100

At a glance

Generic name	Moxonidine 0.2 MG
Sponsor	Italo Biaggioni
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Autonomic Determinants of POTS - Pilot 2 (EARLY_PHASE1)
Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity (PHASE1)
Role of Sympathetic Activation in Ischemia Reperfusion Injury (PHASE4)
Polycystic Ovary Syndrome - Improving Outcomes (PHASE4)
Moxonidine for Prevention of Post-ablation AFib Recurrences (PHASE4)
Treatment of Adiposity Related hypErTension (TARGET) (PHASE4)
Moxonidine in Patients Undergoing Vascular Surgery (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Moxonidine 0.2 MG CI brief — competitive landscape report
Moxonidine 0.2 MG updates RSS · CI watch RSS
Italo Biaggioni portfolio CI